Business Wire (press release) Hypoglycemia: Increased risk of hypoglycemia when used in combination with a sulfonylurea (SFU). Clinicians may consider reducing the SFU dose to minimize risk of hypoglycemia. It is possible that use of BYDUREON with other glucose-independent ... and more »
University of Michigan Health System News (press release) They are: sulfonylurea , which increases insulin levels directly; a DPP-4 inhibitor, which indirectly increases insulin levels by increasing the effect of a naturally occurring intestinal hormone; and a GLP-1 agonist, which increases the amount of ...
DailyFinance When JANUVIA was used in combination with a sulfonylurea or insulin, medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea or insulin may be required to ... and more »
Everyday Health People taking insulin or sulfonylurea drugs, such as glipizide and glyburide, to manage their diabetes are at the greatest risk for hypoglycemia. In addition, older adults with cognitive problems may not recognize initial warning signs of hypoglycemia ...
Fort Mills Times When JANUVIA was used in combination with a sulfonylurea or insulin, medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea or insulin may be required to ... and more »
EON: Enhanced Online News (press release) ... two late-breaker abstracts. Linagliptin is an inhibitor of the enzyme DPP-4 which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that are involved with regulating blood sugar ...
Everyday Health People taking insulin or sulfonylurea drugs, such as glipizide and glyburide, to manage their diabetes are at the greatest risk for hypoglycemia. In addition, older adults with cognitive problems may not recognize initial warning signs of hypoglycemia ... and more »
NHS Choices Currently, GLP-1 agonists may be considered for people whose diabetes has not been controlled by standard first-line treatments, such as metformin and sulfonylurea , and who are obese (BMI above 35kg/m2). The National Institute for Health and Care ... and more »
Business Wire (press release) ... two late-breaker abstracts. Linagliptin is an inhibitor of the enzyme DPP-4 which breaks down the incretin hormones glucagon-like pep...
Diabetes Health (press release) Better yet, when you participate in studies like this it's typical to have your regular diabetes drugs provided for free (in my case, metformin and a sulfonylurea ), along with free regular physical exams, including A1c's, electrocardiograms, blood ...
